S-1: Cellectar Biosciences Files for Resale of Up to 19.2 Million Common Shares Following Warrant Inducement

Cellectar Biosciences is registering for resale up to 19,221,348 shares of its common stock by selling stockholders after a warrant inducement transaction.

Summary

• Cellectar Biosciences, a late-stage clinical biopharmaceutical company, has filed a registration statement for the resale of up to 19,221,348 shares of its common stock.
• These shares are issuable upon the exercise of common stock purchase warrants issued to selling stockholders in a warrant inducement transaction that closed on July 21, 2024.
• The company will not receive any proceeds from the resale of these shares by the selling stockholders, but will receive proceeds from the cash exercise of any Inducement Warrants.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol CLRB, and the last reported sale price on January 28, 2025, was $0.2592.
• The company recently implemented a workforce reduction plan, completed by the end of the fourth quarter 2024, reducing its overall workforce by approximately 60% to decrease annual operating costs by approximately $7.5 million.
• The company estimates it will incur aggregate severance costs of approximately $1.7 million, primarily in the fourth quarter of 2024 and first quarter of 2025.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focusing on factual information regarding the stock offering and recent company developments. The workforce reduction and potential financial difficulties are negative factors, while the potential capital raise and ongoing clinical trials are positive.

Positives

• The company will receive proceeds from the cash exercise of any Inducement Warrants, estimated at $73.3 million if all warrants are exercised.
• The workforce reduction plan is expected to decrease annual operating costs by approximately $7.5 million.

Negatives

• The company will not receive any proceeds from the resale of the shares of common stock by the selling stockholders.
• The company estimates severance costs of approximately $1.7 million related to the workforce reduction.

Risks

• The company will require additional capital to continue operations and may have difficulty raising it.
• The company relies on a collaborative outsourced business model, and disruptions with third-party collaborators may impede the ability to gain FDA approval and delay or impair commercialization of any products.
• The company cannot assure the successful development and commercialization of its compounds in development.
• Failure to meet Nasdaq's continued listing requirements could result in the delisting of the company's common stock.
• The sale of a substantial number of shares of the company's common stock in the public market could adversely affect the prevailing market price.

Future Outlook

The company plans to continue actively pursuing financing alternatives and strategic options for the further development and commercialization of iopofosine I-131.

Industry Context

The document relates to the biopharmaceutical industry, specifically concerning a company focused on cancer treatments and drug delivery platforms. The company is navigating the regulatory landscape (FDA) and financial markets to advance its clinical programs.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• However, it mentions that the company's outcomes in the CLOVER-WaM study exceed real-world data for Waldenstrom's macroglobulinemia treatment.
• It also notes that the company's toxicity profile for iopofosine I 131 is consistent with previously reported safety data.

Related Party Transactions

• The document mentions that certain selling stockholders have had material relationships with the company within the past three years due to their ownership of the company's securities.
• The document also details a private placement in September 2023 with certain accredited investors, including ADAR1 Partners, LP, certain entities associated with AIGH Capital Management LLC, Laurence W. Lytton, certain entities associated with Nantahala Capital Management, LLC and certain entities associated with Rosalind Advisors, Inc., pursuant to which the Company agreed to issue and sell, in a private placement, (i) 1,225 shares of Series E-1 Convertible Voting Preferred Stock, par value $0.0001 per share (the Series E-1 Preferred Stock), (ii) Tranche A Warrants (the Tranche A Warrants) to acquire shares of Series E-3 Convertible Voting Preferred Stock and (iii) Tranche B Warrants (the Tranche B Warrants, together with the Tranche A Warrants, the Warrants) to acquire shares of Series E-4 Convertible Voting Preferred Stock, par value $0.00001 per share (the Series E-4 Preferred Stock and together with the Series E-3 Preferred Stock, the Warrant Shares) for an aggregate offering price of $24.5 million.
• The document also details a warrant exercise inducement offer letters (the Inducement Letters) with certain accredited investors, including ADAR1 Partners, LP, certain entities associated with AIGH Capital Management LLC, Laurence W. Lytton, certain entities associated with Nantahala Capital Management, LLC, certain entities associated with Kingsbrook Partners LP, Triple Gate Partners, LP, Bigger Capital Fund, LP, District 2 Capital Fund, LP, Healthcare Opportunities Master Fund, LP, The Hewlett Fund, LP and certain entities associated with Rosalind Advisors, Inc., who are holders of the Tranche B Warrants, which were originally issued on September 8, 2023, pursuant to which such holders agreed to exercise for cash their Tranche B Warrants to purchase an amount of shares of the Series E-4 Preferred Stock which is convertible to 6,739,918 shares of the Companys common stock, in the aggregate, at a reduced, as-converted common stock exercised price of $2.52 per share, in exchange for the Companys agreement to issue new warrants.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of new shares upon exercise of the inducement warrants.
• Employees have been impacted by the workforce reduction plan.
• The company's ability to continue its research and development programs depends on securing additional funding.

Next Steps

• The selling stockholders may offer or resell the shares from time to time through public or private transactions.
• The company intends to use any proceeds from the cash exercise of the Inducement Warrants for working capital and general corporate purposes.
• The company is pursuing strategic options for the further development and commercialization of iopofosine I-131.
• The company is planning to initiate a Phase 1 imaging and dose escalation safety study for CLR 121225 in the first half of 2025.
• CLR 121125 is expected to initiate a Phase 1b dose finding study in the first half of 2025.

Key Dates

Keywords

common stock, warrants, resale, inducement, Cellectar Biosciences, offering, CLRB, FDA, iopofosine, clinical trials, biopharmaceutical, cancer